Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRC105 + Chemo/Bevacizumab in NSCLC
NCT03780010Phase 1Completed
- Sponsor
- TRACON Pharmaceuticals, Inc.
- Start
- Sep 2015
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of carotuximab in non-small cell lung cancer (NSCLC), sponsored by TRACON Pharmaceuticals, Inc. Primary endpoint: Treatment-Emergent Adverse Events. Started Sep 2015; status: completed.
02
Drugs
carotuximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03780010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03780010.